Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	31.08	1.2	0.14	0.3	24
Revenue Growth (YoY)	2481.48%	766.19%	-53.36%	-98.76%	-92.55%
Cost of Revenue	84	58.97	52.52	55.05	153.05
Gross Profit	-52.92	-57.77	-52.38	-54.75	-129.06
Selling, General & Admin	131.9	112.54	48.08	32.34	44.23
Operating Expenses	131.9	112.54	48.08	32.34	44.23
Operating Income	-184.82	-170.31	-100.46	-87.09	-173.29
Interest Expense	-15.58	-13.1	-2.78	-0.8	-14.54
Interest & Investment Income	12.29	7.73	1.6	0.13	2.77
EBT Excluding Unusual Items	-188.1	-175.68	-101.64	-87.76	-185.06
Merger & Restructuring Charges	-	-	-	-	-5.5
Gain (Loss) on Sale of Assets	-	-	-	-	132.59
Asset Writedown	-	-	-	-	-1.6
Other Unusual Items	-12.3	-1.44	-0.3	-	1
Pretax Income	-200.4	-177.12	-101.94	-87.76	-58.57
Net Income	-200.4	-177.12	-101.94	-87.76	-58.57
Net Income to Common	-200.4	-177.12	-101.94	-87.76	-58.57
Shares Outstanding (Basic)	320	221	166	146	111
Shares Outstanding (Diluted)	320	221	166	146	111
Shares Change (YoY)	44.73%	33.42%	13.79%	31.41%	-5.06%
EPS (Basic)	-0.63	-0.80	-0.62	-0.60	-0.53
EPS (Diluted)	-0.63	-0.80	-0.62	-0.60	-0.53
Free Cash Flow	-179.81	-162.37	-90.18	-88.24	-143.06
Free Cash Flow Per Share	-0.56	-0.73	-0.54	-0.61	-1.29
Gross Margin	-170.25%	-	-	-	-
Operating Margin	-594.63%	-14145.35%	-72273.38%	-29224.83%	-722.17%
Profit Margin	-644.78%	-14710.88%	-73341.01%	-29448.99%	-244.11%
Free Cash Flow Margin	-578.52%	-13485.63%	-64875.54%	-29610.07%	-596.19%
EBITDA	-184.28	-169.76	-100.03	-86.8	-170.35
D&A For EBITDA	0.53	0.55	0.43	0.29	2.93
EBIT	-184.82	-170.31	-100.46	-87.09	-173.29
Revenue as Reported	31.08	1.2	0.14	0.3	24

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q